BIO Announces Life Sciences Companies Selected to Present at the 9th Annual BIO Investor Forum

WASHINGTON, D.C. (Monday, August 23, 2010) The Biotechnology Industry Organization (BIO) today announced the initial selection of 2010 presenting companies for the 9th Annual BIO Investor Forum, taking place at the Palace Hotel in San Francisco, Calif. on October 5-6.

“Each year, the BIO Investor Forum attracts hundreds of venture and institutional investors who want to see a highly selective roster of private and emerging public life science companies that warrant financing” said Alan Eisenberg, executive vice president, Emerging Companies & Business Development at BIO. “Of particular interest for many venture investors, we have created a new Discovery Track of very early stage companies based on input from technology transfer offices, business plan competitions, and venture investors themselves.  BIO believes this expanded forum addresses the current industry environment, in which many investors are looking at companies with demonstrable results as well as those much earlier in development.”

BIO and the conference advisory committee established the criteria for presenting companies. The advisory committee is comprised of members from top-tier firms focused on investing and banking in the life sciences industry in addition to executives from emerging and leading biotech companies. Following are the members of the 9th Annual BIO Investor Forum Advisory Committee:

·         Guarav Aggarwal, MD, Managing Director, Panorama Capital

·         Brian Atwood, Managing Director, Versant Ventures

·         Hany Awadalla, Managing Director, Rodman & Renshaw, LLC

·         Alexis Borisy, Entrepreneur in Residence, Third Rock Ventures

·         Jim Healy, MD, PhD, General Partner, Managing Director, Sofinnova Ventures

·         Michael King, Jr., Managing Director, Equity Research, Wedbush PacGrow Life Sciences

·         Ron Laufer, MD, MPH, Senior Managing Director, MedImmune Ventures

·         John Leone, Partner, Paul Capital

·         Evan McCulloch, Vice President & Portfolio Manager, Franklin Templeton Investments

·         George Milstein, Managing Director, Life Sciences Mergers and Acquisitions, Wedbush PacGrow Life Sciences

·         David Mott, General Partner, NEA

·         James Sapirstein, RPh, CEO & President, Tobira Therapeutics

The BIO Investor Forum will feature more than 140 private and public emerging life science company presentations representing new therapeutic and diagnostic companies from around the world. 

The following companies will present at the 9th Annual BIO Investor Forum:
Advaxis Inc. ADXS 
Affymax Inc AFFY
Alimera Sciences ALIM
Allon Therapeutics Inc. TSE: NPC
Allozyne, Inc.
Aradigm Corp. OTC: ARDM
BioRelix, Inc.
BioSante Pharmaceuticals Inc. BPAX
Cara Therapeutics, Inc.
Cell Therapeutics Inc. CTIC
Cellerant Therapeutics, Inc.
Cleveland BioLabs, Inc. CBLI 
Constellation Pharmaceuticals, Inc.
CorMedix Inc. AMEX: CRMD
Curis Inc. CRIS 
Cyclacel Pharmaceuticals Inc. CYCC 
Cytos Biotechnology AG
Fate Therapeutics, Inc.
FivePrime Therapeutics, Inc.
GlycoMimetics, Inc.
Idenix Pharmaceuticals Inc. IDIX  
Inimex Pharmaceuticals, Inc.
LigoCyte Pharmaceuticals, Inc.
Living Cell Technologies Ltd. ASX:LCT  
Mirna Therapeutics, Inc.
Nuon Therapeutics, Inc.
Oncolytics Biotech Inc. ONCY
Palatin Technologies AMEX: PTN
PLx Pharma, Inc.
Relypsa, Inc.
RXi Pharmaceuticals Corp. RXII
Sangart, Inc.
Somaxon Pharmaceuticals Inc. SOMX
Sucampo Pharmaceuticals, Inc. SCMP 
Syndax Pharmaceuticals, Inc.
Tengion Inc. TNGN 
Tetraphase Pharmaceuticals, Inc.
Threshold Pharmaceuticals Inc. THLD
Tobira Therapeutics

Transdel Pharmaceuticals, Inc. OTC: TDLP
Virdante Pharmaceuticals, Inc.
Vitae Pharmaceuticals, Inc.

This year’s BIO Investor Forum will also debut a special “Discovery Track” featuring young companies that have met the selection criteria established by BIO and the 2010 BIO Investor Forum advisory committee.  The following companies will present on the Discovery Track:
Catena Pharmaceuticals, Inc.
ConjuGon Inc.
Diffusion Pharmaceuticals LLC
Histogen, Inc.
MabVax Therapeutics, Inc.
Mithridion, Inc.
MedDEV Inc.
NanoCor Therapeutics, Inc.
Neuraltus Pharmaceuticals Inc.
NKT Therapeutics Inc.
Revotar Biopharmaceuticals AG
Savara Pharmaceuticals
TxCell S.A
Zymeworks Inc.

Additional presenting companies are confirmed each day. For the most up-to-date list, please visit Registration is complimentary for qualified investors and members of the media.

About the 9th Annual BIO Investor Forum

The BIO Investor Forum is a national investor conference featuring private and emerging public companies.  The meeting attracts healthcare venture capital and public market investors and research analysts.  In addition, the BIO Investor Forum draws business development executives from global pharmaceutical and biotechnology companies.


Upcoming BIO Events

BIO India
September 21 - 22, 2010
Hyderabad, India

BIO’s Livestock Biotechnology Summit
September 28-30, 2010,
Sioux Falls, SD

BIO Investor Forum
October 5-6, 2010
San Francisco, CA

BIO Intellectual Property Counsels Committee Fall Conference and Committee Meeting
October 18-20, 2010
Boston, MA

Advanced Business Development Course
November 12-14, 2010
Munich, Germany

BIO-Europe International Partnering Conference
November 15-17, 2010
Munich, Germany

Pacific Rim Summit on Industrial Biotechnology and Bioenergy
December 11-14, 2010
Honolulu, HI 

About BIO

BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtech Now, an online portal and monthly newsletter chronicling “innovations transforming our world.” Subscribe to BIOtech Now.